Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

tags : Als    symbols : Lly    save search

AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43
Published: 2023-02-07 (Crawled : 16:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M twitter stocktwits trandingview |
Health Technology
| | O: -0.48% H: 1.46% C: 1.08%
ACIU | $2.33 -2.1% -2.15% 320K twitter stocktwits trandingview |
Health Technology
| | O: 1.27% H: 2.08% C: 0.83%

tdp-43 als grants
Global Generic Injectables Market Research Report 2022: Expiration of Branded Drug Patents & Rising Approvals for Generic Injectable Drugs
Published: 2022-03-15 (Crawled : 23:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M twitter stocktwits trandingview |
Health Technology
| | O: 0.87% H: 0.27% C: -0.51%
SNY | News | $46.66 -2.16% -2.21% 1.7M twitter stocktwits trandingview |
Health Technology
| | O: 0.82% H: 0.0% C: 0.0%

als drug patent research approval report
Centessa Pharmaceuticals Expands Management Team and Adds to Extensive Development Expertise
Published: 2022-03-07 (Crawled : 13:30) - biospace.com/
CNTA | News | $9.475 0.8% 0.79% 2.2M twitter stocktwits trandingview |
Manufacturing
| | O: -8.81% H: 10.7% C: -3.99%
LLY | News | $732.2 -1.81% 0.18% 2.1M twitter stocktwits trandingview |
Health Technology
| | O: 2.08% H: 0.0% C: 0.0%

als
Entos Pharmaceuticals Announces Senior Leadership Appointments to Expand Executive Team and Accelerate Growth
Published: 2022-03-03 (Crawled : 14:30) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M twitter stocktwits trandingview |
Health Technology
| | O: 2.08% H: 1.86% C: 1.5%
LJPC | $6.22 0.0% twitter stocktwits trandingview |
Health Technology
| | O: 1.9% H: 1.63% C: -2.33%

als ces cel growth
Avadel Pharmaceuticals Appoints Dr. Douglas Williamson as Chief Medical Officer
Published: 2022-02-14 (Crawled : 13:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M twitter stocktwits trandingview |
Health Technology
| | O: -2.3% H: 1.23% C: 0.29%
AVDL | $17.655 -2.41% -2.46% 440K twitter stocktwits trandingview |
Health Technology
| | O: 0.0% H: 3.03% C: 2.42%

als
Vanda Pharmaceuticals Reports Results from the Phase III Study of Tradipitant in Gastroparesis
Published: 2022-02-04 (Crawled : 12:30) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M twitter stocktwits trandingview |
Health Technology
| | O: -2.52% H: 0.0% C: 0.0%
VNDA | $4.57 -1.3% -1.31% 1.5M twitter stocktwits trandingview |
Health Technology
| | O: -22.12% H: 0.0% C: 0.0%

als report results
Eagle Pharmaceuticals Announces Commercial Availability of PEMFEXY™
Published: 2022-02-01 (Crawled : 12:30) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M twitter stocktwits trandingview |
Health Technology
| | O: 1.37% H: 0.0% C: 0.0%
EGRX | $4.58 -3.98% -4.15% 95K twitter stocktwits trandingview |
Health Technology
| | O: 2.56% H: 0.0% C: -1.08%

als commercialization
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Published: 2022-01-08 (Crawled : 00:20) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
RIGL | $1.125 -1.32% -1.33% 6.4M twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist

als nasdaq granted grant
Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications
Published: 2022-01-06 (Crawled : 12:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M twitter stocktwits trandingview |
Health Technology
| | O: -2.81% H: 0.0% C: 0.0%

als research collaboration
Eli Lilly’s Two-Year Ambition Includes Alzheimer’s Approvals
Published: 2021-12-15 (Crawled : 19:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M twitter stocktwits trandingview |
Health Technology
| | O: 4.7% H: 0.0% C: 0.0%

alzheimer als approval alzheimer’s alzheimer's
Neurimmune and TVM Capital Life Science Announce the Initiation of AL-S Pharma's Phase 2 Study of AP-101 for the Treatment of ALS
Published: 2021-11-18 (Crawled : 21:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M twitter stocktwits trandingview |
Health Technology
| | O: 2.14% H: 0.69% C: -0.26%

treatment phase 2 life science als
Gainers vs Losers
62% 38%

Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M twitter stocktwits trandingview |
Consumer Services

BOF | $1.99 70.09% 41.21% 110M twitter stocktwits trandingview |

ILAG | $0.51 6.03% 40.62% 1.7M twitter stocktwits trandingview |

LICN | $0.941 68.04% 40.49% 15M twitter stocktwits trandingview |

AMST | $3.31 65.5% 39.58% 70M twitter stocktwits trandingview |
Technology Services

MTC | $3.615 61.38% 38.04% 9.3M twitter stocktwits trandingview |
Technology Services

WIMI | $1.15 58.53% 36.92% 19M twitter stocktwits trandingview |
Technology Services

AIH | $0.45 12.5% 30.92% 320K twitter stocktwits trandingview |
Health Services

MULN | News | $3.78 38.46% 27.78% 13M twitter stocktwits trandingview |
Information

RILY | $29.86 37.48% 27.26% 12M twitter stocktwits trandingview |
Finance


Your saved searches
Save your searches and get alerts when important news are released.